نتایج جستجو برای: 466 and 177

تعداد نتایج: 16828932  

Journal: :Advances in Radiation Oncology 2021

Journal: :Japanese Journal of Radiological Technology 1991

2011
Kazunori Hamamura Momoko Tsuji Hiroshi Hotta Yuki Ohkawa Masataka Takahashi Hidenobu Shibuya Hideyuki Nakashima Yoshio Yamauchi Noboru Hashimoto Hisashi Hattori Minoru Ueda Keiko Furukawa Koichi Furukawa

Department of Biochemistry II, and Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, 466-0065, and Department of Biomedical Sciences, Chubu University College of Life and Health Sciences, 1200 Matsumoto-cho, Kasugai 487-8501, Japan Running head: Yes enhances malignancies of melanomas under GD3 expression Correspondence: D...

2012
Geetanjali Arora Jaya Shukla Sourabh Ghosh Subir Kumar Maulik Arun Malhotra Gurupad Bandopadhyaya

BACKGROUND Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin Receptors (SSTRs) on NETs. It is, however, limited by high uptake and retention of radiolabeled peptide in kidneys resulting in unnecessary radiation exposure thus causing nephrotoxicity. Employing a nanocarrier to deliver PRRT drugs specifi...

Journal: :International Astronomical Union Colloquium 2000

Journal: :Nuclear Data Sheets 2019

Journal: :Genetics 2003
Y Kakizaki

INTRODUCTION. . . . . . . . ............ 168 Material and methods.. . ............ 168 Results of experiments.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169 DISCUSSION. .. ................... ................................... 174 SWMARY ....................................................................... 177 LITERATFR...

Journal: :In vivo 2011
Martin Behe Karen Alt Friederike Deininger Patrick Bühler Ulrich Wetterauer Wolfgang A Weber Ursula Elsässer-Beile Philipp Wolf

AIM The goal of the present study was to test the (177)Lu-labelled anti-PSMA monoclonal antibody 3/F11 ((177)Lu-DOTA-3/F11) as a new radioimmunotherapeutic agent in a prostate cancer SCID mouse xenograft model. MATERIALS AND METHODS The mAb 3/F11 was (177)Lu labelled using 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as chelating agent. DOTA-3/F11 was tested for cell bindin...

2009
Brendan Juba

We think of this as saying that under some mild conditions on our probability space, the distribution of the linear form Q is roughly the same, regardless of the actual underlying distribution. There are, of course, a family of different central limit theorems, with different “mildness conditions” leading to different notions of the closeness of the resulting distributions. As “central limit th...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید